Brind.

Collegium Pharmaceutical acquired Ironshore Therapeutics in 2024 and is scheduled to present pain studies at PAINWeek 2025.

4 reports, 3 independent Updated Sep 2
Gone quiet Reached 3 outlets in its first 24 hours
Reports
4
Developments
2
Repetition
75%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

Collegium Pharmaceutical acquired Ironshore Therapeutics in 2024 and is scheduled to present pain studies at PAINWeek 2025.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Collegium Pharmaceutical reported on August 14, 2025, that the company enjoys steady growth across its pain portfolio, driven by its successful ADHD therapy product, Jornay.Sub-event
  2. Collegium announces acquisition of Ironshore Therapeutics and upcoming pain study presentations.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Insider MonkeyCollegium Pharmaceutical, Inc. (COLL) to Present 9 Pain Studies at PAINWeek 2025 We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Collegium Pharmaceutical, Inc
  • Insider MonkeyCollegium Pharmaceutical, Inc. (COLL) Highlights Real-World Evidence at PAINWeek 2025 We recently compiled a list of the 10 Overlooked Healthcare Stocks to Invest in. Collegium Pharmaceutical, Inc. s
  • GlobeNewswireCollegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting STOUGHTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it
  • CNW GroupInnocan's Findings to be Showcased in Scientific Poster Reception at PAINWeek 2025 Conference in Las Vegas, Nevada PAINWeek is the premier US conference in pain management Innocan's Poster "Is Long-A